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Pneumococcal conjugate vaccineBackground: Thirteen-valent pneumococcal conjugate vaccine (PCV13) was introduced in Malawi in
November 2011 and is offered to infants at 6, 10 and 14 weeks of age as part of routine immunisation.
PCV13 is expected to reduce vaccine type (VT) nasopharyngeal carriage, leading to reduced transmission
and herd protection.
Methods: We compared pneumococcal carriage in rural Karonga District, Malawi, pre-vaccine in 2009–
2011 and post-vaccine in 2014 using a combination of cross-sectional and longitudinal analyses.
Nasopharyngeal swabs were collected from a cohort of mother-infant pairs and household members
<16 years. Pneumococci from 2009 to 2011 were serogrouped using latex agglutination and serotyped
by Quellung reaction. In 2014, latex agglutination was used for both steps. Carriage prevalence ratios
using prevalence data from before and after vaccine introduction were calculated by log-binomial regres-
sion, adjusted for age, seasonality and household composition. Participating infants in 2014 received
PCV13 as part of routine immunisation.
Results: VT carriage prior to PCV-13 introduction was 11.4%, 45.1%, 28.2%, 21.2% and 6.6% for 6-week old
infants, 18-week old infants, children 1–4 years, children 5–15 years and mothers, respectively. After vac-
cine introduction, VT carriage decreased among vaccinated 18-week old infants (adjusted prevalence
ratio 0.24 (95%CI 0.08–0.75)), vaccinated children 1–4 years (0.54 (0.33–0.88)), unvaccinated children
5–15 years (0.37 (0.17–0.78)) and mothers (0.34 (0.15–0.79)). No decrease in VT carriage was observed
for 6-week old infants too young to be vaccinated (1.07 (0.38–3.02)) and PCV-13 ineligible children 1–
4 years (0.84 (0.53–1.33)). Non-VT carriage increased only among vaccinated children 1–4 years (1.58
(1.21–2.06)).
Conclusions: There is evidence of reduced VT pneumococcal carriage three years after vaccine introduc-
tion in this rural Malawian population with good vaccine coverage using a 3 + 0 schedule. However car-
riage was sustained among 6-week-old infants and PCV13 ineligible 1–4 year olds, and there was some
indication of serotype replacement in vaccinated 1–4 year olds.
 2018 Univerity of Liverpool. Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction pneumococcus. Although mostly asymptomatic, nasopharyngealStreptococcus pneumoniae (pneumococcus) is a leading cause of
childhood morbidity and mortality worldwide. The nasopharynx is
the primary portal for entry and source for transmission of thecarriage is thought to be a pre-requisite for disease [1]. Asymp-
tomatic carriers are also the main source of pneumococcal trans-
mission, with person-to-person spread occurring in close contact
[1]. Pneumococcal acquisition occurs very early in life in develop-
ing countries, with an observed median time to first acquisition of
only 38.5 days, 45.5 days, 59 days or 8 weeks after birth reported
in Kenya, Thailand-Myanmar, Malawi and Bangladesh respectively
[2–5]. This early and intense exposure in infancy is likely to play a
role in the high disease incidence experienced in these settings.
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tive against vaccine type (VT) invasive pneumococcal disease (IPD)
[6–8]. PCV reduces nasopharyngeal carriage in vaccinated individ-
uals [9], allowing for a herd effect, as observed in many high-
income countries [10–12] and some low-income countries [8,13].
Serotype replacement is a concern [14,15], but although increases
in non-vaccine type (NVT) IPD have been observed after PCV intro-
duction in most study sites, rates of overall IPD have dropped as a
result of a decrease in VT pneumococci [16]. Evidence is mainly
available for high-income countries, however introduction of PCV
in low-income countries could result in a higher rate of serotype
replacement due to a high background rate of pneumococcal car-
riage. Also, the HIV-burden in many countries could have an effect
on serotype replacement, as carriage of NVT pneumococci was
found to be high in HIV-infected adults prior to PCV13 introduction
despite established antiretroviral treatment [17].
Thirteen-valent pneumococcal conjugate vaccine (PCV13) was
introduced in the Malawian infant immunisation programme in
November 2011 using a ‘‘3 + 0” schedule with doses given at 6,
10 and 14 weeks. Initial PCV13 catch-up vaccination was con-
ducted at the time of introduction with infants <1 year of age at
date of first dose receiving 3 doses at 1-month intervals. Vaccine
coverage with 3 doses PCV13 at 1 year of age among those eligible
for PCV13 in the birth cohort was 89.4% in Karonga District,
Malawi, in 2014 [18]. Vaccine coverage with 3 doses PCV13 in
the catch-up cohort was 49.8% [18]. We compared pneumococcal
carriage in Karonga District, Malawi, before and after introduction
of PCV13, in order to review the effect of the pneumococcal vacci-
nation programme on VT and NVT carriage.2. Materials and methods
2.1. Study population and design
The study was conducted in the area covered by the Karonga
Health and Demographic Surveillance System (HDSS) in northern
Malawi [19]. Established in 2002, the HDSS covers an area of
135 km2 and provides continuous population surveillance with
all births, deaths and migrations recorded. The population size
was 34,111 in January 2009, increasing approximately 2.5% per
annum. The area has an annual birth cohort of about 1500. In
2010 life expectancy at birth was 69.4 years, with infant and
under-five mortality rates of 35.0 and 59.1 per 1000 live births,
respectively [19]. Main sources of income in the KHDSS area are
subsistence farming, fishing and small-scale trading. HIV-
prevalence in women of childbearing age ranged between 3% in
women 15–24 years and 16% in women 30–39 years in
2008/2009 [20], remaining relatively stable between 2008 and
2014 [21]. ART has been available in the government clinic within
the study catchment area since 2006; ART uptake in the HDSS was
estimated to be at least 60% of those eligible in mid-2008 [20].
Longitudinal household pneumococcal carriage studies were
conducted in 2009–2011 before PCV13 introduction and 2.5 years
post PCV13 introduction in 2014. Here we present a combination
of cross-sectional and longitudinal data analyses to compare pneu-
mococcal carriage prevalence and pneumococcal acquisition in
infants between the pre- and post-PCV13 periods. An overview of
the data collection and analyses can be found in Supplementary
Fig. 1. A longitudinal design was chosen to study pneumococcal
transmission within households, results for which have been pub-
lished elsewhere [5].
The methods and results of the 2009–2011 study have previ-
ously been published [5]. Briefly, pregnant women living in the
HDSS area were recruited from antenatal clinics in two ruralhospitals between January 2009 and December 2010. These
women were then followed up at their home after delivery, collect-
ing nasopharyngeal swabs from the mother, the infant, and other
household members willing to participate at 6, 10, 14, 18, 22, 26,
30, 34, 40, 46, and 52 weeks of the infant’s age.
In 2014, recruitment of mother-infant pairs took place in the
postnatal clinics of two rural hospitals between April and July of
the same year. All mother-infant pairs living within the HDSS area
who were discharged within one week of delivery were eligible for
inclusion in the study. The first 44 mother-infant pairs recruited
were sampled longitudinally: nasopharyngeal swabs were col-
lected at their household from the infant, mother, and any other
children 1–4 years in the household at 6, 8, 10, 12, 14, 16, 18 weeks
of the infant’s age. The remaining mother-infant pairs recruited
were sampled only once at 6 weeks of the infant’s age. This was
done as a cross-sectional component to minimise logistical chal-
lenges associated with longitudinal sample collection while
increasing the number of samples and statistical power of the
study in calculating carriage at 6 weeks of age (prior to receiving
first dose of PCV13).
Older children (5–15 years) willing to participate were included
only in the cross-sectional component of the 2014 study. No adults
other than the mother were included in the 2014 study. This deci-
sion was based on experience from the 2009–2011 study demon-
strating frequent refusal of adults other than the mother and
poor retention of older children in longitudinal sampling. HIV-
status of the mother was transcribed from her ‘‘health passport”
(patient-held health record) or the mother was asked for her
HIV-status verbally if the health passport was unavailable. Only
the results for HIV-negative mothers were included in the analy-
ses: previous work showed that pneumococcal carriage was higher
in HIV-infected than in HIV-uninfected mothers [5]. HIV exposure
was not found in previous work to be associated with differences
in pneumococcal carriage prevalence or serotype distribution in
childhood [5]; therefore all samples from children were included
regardless of the HIV status of the mother.
Recruited infants were offered routine vaccinations, including
PCV13 in 2014, at 6, 10, and 14 weeks of age. Vaccination status
of other children 1–4 years in the household was obtained from
HDSS records. Follow-up ceased if the infant died or moved outside
the study area, consent was withdrawn or there was a failure to
sample on two sequential visits.2.2. Laboratory procedures
Nasopharyngeal samples were collected, processed and anal-
ysed per WHO recommendations [22] as described previously
[5]. A calcium alginate swab (Medical Wire & Equipment, Corsham,
UK) was inserted into the posterior nasopharynx. The swab was
transported in skim milk-tryptone-glucose-glycerol medium. Inoc-
ulated vials were stored at 20 C within 6 h of collection, and
were frozen at 80 C within days until tested. Samples (30 mL)
were cultured on gentamicin (5 mg/mL) sheep blood agar plates
and incubated overnight at 37 C with 5% carbon dioxide. Pneumo-
cocci were identified by morphology and sensitivity for optochin. A
single colony was selected from the primary plate and a secondary
plate was grown to obtain pure growth. Pneumococci from 2009 to
2011 were serogrouped using latex agglutination and serotyped by
Quellung reaction. In 2014, latex agglutination was used for both
steps. Both assays used standard antisera (Statens Serum Institute
Denmark). The 13-valent latex serotyping kit was used to identify
individual VT (1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, 23F) and
provide some detail on NVT serogroup (e.g. 7A/7B/7C). Serotyping
for NVT was not done due to budget constraints.
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Analyses comparing the pre- and post-PCV13 period were
season-matched: only the pre-PCV13 samples collected in April-
August of each year were included because post-PCV13 sampling
was limited to these months. Seasonality was shown in the pre-
PCV13 study to be a strong predictor of pneumococcal carriage,
with carriage being highest in the cold season (May-August) [5].
Carriage prevalence in the pre- and post-PCV13 periods was calcu-
lated for infants at 6 weeks (prior to receiving PCV13 in 2014),
infants at 18 weeks (post receiving PCV13 in 2014), children
1–4 years, children 5–15 years and HIV-negative mothers. To
increase the power of the analysis, repeated longitudinal samples
for the mothers and children 1–15 years in the household were
used in the cross-sectional analysis.
Carriage prevalence ratios (PR) were calculated for the periods
before and after vaccine introduction. Potential confounders were
identified by testing the association between variables and the vac-
cine period and included in the multivariate models when p < 0.1.
Adjusted prevalence ratios (APR) were calculated using log-
binomial regression, or Poisson regression with robust standard
errors if the log-binomial regression failed to converge [23]. Mixed
models with individual-level random effects were fitted to exam-
ine within-person clustering as a result of the longitudinal sam-
pling of mothers and children 1–15 years.2.4. Longitudinal analyses
Pneumococcal acquisition in infants was assessed by survival
analysis including Kaplan-Meier plots, log-rank tests, and cox pro-
portional hazard models adjusted for the number of children
<5 years in the household [24]. An episode of carriage was defined
as isolation of a pneumococcus from one or more consecutive sam-
ples. New acquisition was defined as the identification of a sero-
type not identified at the previous two sampling times. NVT2009-2011: pre-vaccination period
9 departed from study area
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1 other 
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288 children 5-15 years
in households 
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recruited
Samples included only if collected in months April - August
Fig. 1. Flowchart of recruitment and availability of nasopharyngeal samples of mothers
PCV13 periods.serogroups without further distinction (e.g. 7A/7B/7C) were
regarded to be the same serotype. Pneumococcal isolates identified
in the first sample were regarded as new acquisitions. The date of
acquisition was defined as the midpoint between the last negative
and the first positive result. To allow for comparison of mean time
to first acquisition between 2009 and 2011 and 2014, only samples
from weeks 6, 10, 14 and 18 were used in the survival analyses
(weeks sampled in both 2009–2011 and 2014). The reduction in
pneumococcal acquisition at 10, 14 and 18 weeks was calculated
as 1-RR.2.5. Ethics
Informed written consent was obtained from participating
mothers. Ethical approval was granted by the National Health
Sciences Research Committee in Malawi (#490, #1232), the Lon-
don School of Hygiene and Tropical Medicine (# 5345) and the
University of Liverpool (#670) ethics committees.3. Results
3.1. Study participants and samples
Fig. 1 provides a flowchart of recruitment and availability of
samples in the pre- and post-PCV13 period. In 2009–11, 185
mother infant pairs were recruited. Follow-up ceased prematurely
for 24 infants (13.0%) because they departed from the study area
(n = 9), died within the first year of life (n = 7), were lost to
follow-up (n = 6), were withdrawn from the study (n = 1) or left
for other reasons (n = 1). For this seasonality-matched cross-
sectional analysis comparing pneumococcal prevalence in the
pre- and post-PCV13 period, 1391 samples were available from
70 6-week old infants, 71 18-week old infants, 109 children
1–4 years, 144 children 5–15 years and 135 HIV-negative mothers
recruited from a total of 166 households. In total 134 samples from54 children 1-4 years
121 children 5-15 years
in households 
2014: post-vaccination period
148 mother-infant pairs 
participated  
4 lost to follow up 
her-infant pairs in 
inal component 
104 mother-infant pairs in 
cross-sectional component 
346 samples available for 
analysis:  
- 102 from HIV-negative mothers 
- 104 from infants
- 51 from children 1-4 years 
- 89 from children 5-15 years
mples available for analysis:
om 42 HIV-negative mothers 
om 44 infants
om 23 children 1-4 years 
s 
152 mother-infant pairs 
recruited (April – August) 
, infants, and children 1–15 years in Karonga District, Malawi in the pre- and post-
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pneumococcal acquisition in the first 18 weeks of life in the pre-
and post-PCV13 period.
In 2014, 152 mother-infant pairs were recruited; four mother-
infant pairs were lost to follow up and 148 mother-infant pairs
participated in the study: the first 44 in the longitudinal compo-
nent, the latter 104 in the cross-sectional component. Documented
HIV test results were available for 88.5% (131/148) mothers. Four
(2.7%) mothers were HIV-positive (two with documented, two
with verbal report). Of the HIV-negative mothers, 97.9%
(141/144) were tested within the last year. In the longitudinal
component there were 23 children 1–4 years in participating
households; at least one nasopharyngeal sample was collected
from all. In the cross-sectional component there were 54 children
1–4 years and 121 children 5–15 years in the participating house-
holds: a nasopharyngeal sample was collected from 51 (94.4%) and
89 (73.6%) respectively. Four children were included as infant in
the pre-PCV13 and as a child 1–4 years in the post-PCV13 period.
Six samples were lost, leaving 1116 samples for analysis; 770 col-
lected in the longitudinal component, 346 in the cross-sectional
component of the study.
All infants participating in the 2014 study received PCV13 at 6,
10, 14 weeks of age. Among the 77 children 1–4 years, 25 (32.5%)
were age-eligible for vaccination in the birth cohort and had
received full vaccination with PCV13. Twenty-eight children
(36.4%) were age-eligible for vaccination in the catch-up cohort;
15 (53.6%) had received full vaccination, 4 (14.3%) partial vaccina-
tion and 9 (32.1%) no vaccination. Twenty-three children (29.9%)
were not age-eligible for PCV13. One child’s vaccine eligibility
was unknown. No children 5 years or adults received PCV13.3.2. Characteristics of participants
Table 1 shows the characteristics of participants in the pre- and
post-PCV13 periods. Participating children 5–15 years were older,
HIV-negative mothers were younger and there were fewer house-
holds with children <5 years other than the recruited infant in the
post-PCV13 period. Pneumococcal prevalence ratios were adjusted
for age and number of children <5 years in the household, factors
known to be associated with pneumococcal carriage.Table 1
Characteristics of participating mothers, infants, and children 1–15 years in Karo
Pre-PCV13 period (200
Female sex
Infants 6 weeks 35/70 (50.0%)
Infants 18 weeks 33/71 (46.5%)
Children 1–4 years 66/109 (60.6%)
Children 5–15 years 72/144 (50.0%)
HIV-negative mothers 135/135 (100%)
Age in years (mean, sd)
Children 1–4 years 2.7, sd = 0.9
Children 5–15 years 7.8, sd = 2.6
HIV-negative mothers 26.3, sd = 6.9
Number of children <5 years other than
the recruited infant (households)
0: 45/166 (27.1%)
1: 92/166 (55.4%)
2: 29/166 (17.5%)
Information included for individuals with at least one sample result.
sd: standard deviation
1 p-values for the comparison between the pre-PCV13 and post-PCV13 period
numerical data.3.3. Pneumococcal carriage prevalence in the pre- and post-PCV13
period
Fig. 2 shows the pneumococcal carriage prevalence by age
group in the pre- and post-PCV13 periods. Fig. 3 shows the propor-
tion of VT isolates among pneumococcal carriers. The proportion of
VT isolates among pneumococcal carriage was lower in 2014 than
in 2009–2011 for all age groups, except 6-week old infants (Fig. 3).
Table 2 shows the crude and adjusted prevalence ratios for the
pre- and post-PCV13 period. After vaccine introduction, VT carriage
decreased among vaccinated 18-week old infants and vaccinated
children 1–4 years. Although decreased, VT carriage remained
common in vaccinated 1–4 years at 16.5%. VT carriage also
decreased in children 5–15 years and mothers. A decrease in VT
carriage from 28.2% to 22.9% was observed in unvaccinated chil-
dren 1–4 years, but this was not found to be significant. No
decrease was observed for 6-week infants. NVT carriage increased
among vaccinated children 1–4 years only; from 31.2% to 53.4%.
In the post-PCV13 period, VT isolated were 19F (14 individuals),
6B (13) and 6A (10), 19A (7), 9 V (5), 14 (5), 3 (4), 18C (2) and 5(1).3.4. Pneumococcal acquisition in infants
Fig. 4 shows the time to first pneumococcal carriage acquisition
in infants in the pre- and post-PCV13 periods. For acquisition of
any serotype, no difference was observed between the pre- and
post-PCV13 period (median time 55.5 vs. 56.5 days, p = 0.71). After
adjustment for the number of children 1–4 years in the household,
the hazard ratio for pneumococcal colonization in the post-PCV13
compared to the pre-PCV13 period was 1.10 (95%CI 0.63–1.91). For
VT carriage, a difference was observed between the pre- and post-
PCV13 period, with 62.9% (22/35) vs. 27.9% (12/43) of infants
acquiring a VT pneumococcus at least once within the first
18 weeks of life (p = 0.008). After adjustment for the number of
children 1–4 years in the household, the hazard ratio for VT pneu-
mococcal colonization in the post-PCV13 compared to the pre-
PCV13 period was 0.37 (95%CI 0.17–0.81), indicating a 63%
reduction.
Observations in the pre-PCV13 period right-truncated at
18 weeks (maximum observation period post-PCV13 period).nga District, Malawi in the pre- and post-PCV13 periods.
9–11) Post-PCV13 period (2014) p-value1
75/146 (51.4%) 0.97
26/44 (59.1%) 0.26
12/29 (41.4%) (unvaccinated) 0.10
15/38 (39.5%) (vaccinated) 0.04
27/74 (36.5%) (all) 0.002
40/89 (44.9%) 0.54
144/144 (100%) –
3.5, sd = 0.6 (unvaccinated) <0.001
2.1, sd = 0.7 (vaccinated) <0.001
2.7, sd = 1.0 (all) 0.99
8.5, sd = 3.0 0.002
24.2, sd = 6.3 <0.001
0: 79/148 (53.4%)
1: 61/148 (41.2%) <0.001
2: 8/148(5.4%)
; using the Pearson’s v2 test for categorical data and the Student’s t-test for
Fig. 2. Prevalence of carriage of any serotype (A), VT carriage (B) or NVT carriage (C) among mothers, infants and children 1–15 years in Karonga District, Malawi, in the pre-
and post-PCV13 periods.
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24.2% (8/33) in the pre-PCV13 period and 9.3% (4/43) in the post-
PCV13 period, implying a 62% reduction in VT carriage acquisition
for one dose of PCV13. Incidence in weeks 10–14 was 20.6% (7/34)
in the pre-PCV13 period and 4.9% (2/41) in the post-PCV13 period,
implying a 76% reduction in VT carriage acquisition for two doses
of PCV13. Incidence in weeks 14–18 was 40.6% (13/32) in the
pre-PCV13 period and 2.3% (1/44) in the post-PCV13 period, imply-ing a 94% reduction in VT carriage acquisition for three doses of
PCV13. Combining the results for all weeks, the VT carriage reduc-
tion for at least one dose of PCV13 was 81%.
In 2014, infants acquired pneumococci of any serotype at an
earlier age when living with children 1–4 years in the household
(Supplementary Fig. 2). No evidence was found for a difference in
first VT acquisition between infants living with vaccinated or
unvaccinated children 1–4 years (p = 0.73, results not shown).
Table 2
Carriage prevalence and prevalence ratio for pneumococcal carriage among mothers, infa
periods.
Vaccine status,
20141
Carriage prevalence, 2009–2011 (pre
PCV13 introduction)
Carria
PCV13
All serotypes
Infants, 6 wks unvaccinated 27/70 (38.6%) 64/14
Infants, 18 wks fully
vaccinated
53/71 (74.7%) 22/44
Children 1–4
yrs2
unvaccinated 196/330 (59.4%) 53/83
fully
vaccinated
– 72/10
all – 141/2
Children 5–15
yrs
unvaccinated 161/325 (49.5%) 33/89
HIV-negative
mothers
unvaccinated 100/595 (16.8%) 64/41
VT
Infants, 6 wks unvaccinated 8/70 (11.4%) 19/14
Infants, 18 wks fully
vaccinated
32/71 (45.1%) 4/44
Children 1–4
yrs2
unvaccinated 93/330 (28.2%) 19/83
fully
vaccinated
– 17/10
all – 37/20
Children 5–15
yrs
unvaccinated 69/325 (21.2%) 7/89
HIV-negative
mothers
unvaccinated 39/595 (6.6%) 10/41
NVT
Infants, 6 wks unvaccinated 19/70 (27.1%) 45/14
Infants, 18 wks fully
vaccinated
21/71 (29.6%) 18/44
Children 1–4
yrs2
unvaccinated 103/330 (31.2%) 34/83
fully
vaccinated
– 55/10
all – 104/2
Children 5–15
yrs
unvaccinated 92/325 (28.3%) 26/89
HIV-negative
mothers
unvaccinated 61/595 (10.3%) 54/41
1 Fully vaccinated: 3 doses of PCV13; unvaccinated: no doses of PCV13 received; all: in
in addition to the fully vaccinated and unvaccinated.
2 Children 1–4 years: carriage in 2014 of unvaccinated, fully vaccinated and all childr
cinated). Unvaccinated children 1–4 years in 2014: this includes samples from 9 children
23 children who were not age-eligible for PCV13.
3 Adjusted for month of sample collection, number of children 1–4 years in the hous
mixed model, there was negligible individual-level variance for children 1–4 years and
model were reported. Using a generalized linear mixed model, the individual-level varia
4 Log-binomial regression model data did not to converge so results of a Poisson mod
Fig. 3. Proportion of VT isolates among pneumococcal carriers among mothers,
infants and children 1–15 years in Karonga District, Malawi, in the pre- and post-
PCV13 periods.
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This is the first published study on pneumococcal carriage
prevalence after routine introduction of PCV13 in a vaccine-naive
sub-Saharan country using a 3 + 0 schedule. Previous studies were
conducted in Kenya [25,26], The Gambia [27] and South Africa [28],
but different vaccines and/or schedules were used (Supplementary
Table 1). We provide evidence for a reduction in VT carriage three
years after PCV13 introduction in this rural Malawi population. A
direct vaccine effect was obtained immediately after vaccination:
occurrence of any infant pneumococcal acquisition in the first
18 weeks was reduced by 63% when comparing the pre- and
post-PCV13 period. Whilst there is evidence for herd protection
in older children and mothers, VT carriage remained high among
6-week old infants too young to be vaccinated and unvaccinated
children 1–4 years. NVT carriage increased among vaccinated chil-
dren 1–4 years, providing evidence for moderate levels of serotype
replacement in this group.nts and children 1–15 years in Karonga District, Malawi, in the pre- and post-PCV13
ge prevalence, 2014 (post
introduction)
Crude prevalence
ratio (95%CI)
Adjusted prevalence
ratio (95%CI)3
6 (43.8%) 1.14 (0.80–1.61) 0.98 (0.66–1.47)
(50.0%) 0.67 (0.48–0.93) 0.60 (0.42–0.86)4
(63.9%) 1.08 (0.89–1.29) 1.06 (0.86–1.30)4
3 (70.0%) 1.18 (1.01–1.37) 1.08 (0.91–1.28)4
07 (68.1%) 1.15 (1.01–1.30) 1.10 (0.97–1.25)4
(37.1%) 0.75 (0.56–1.00) 0.73 (0.55–0.97)4
8 (15.3%) 0.92 (0.69–1.22) 0.75 (0.47–1.17)
6 (13.0%) 1.14 (0.52–2.47) 1.07 (0.38–3.02)
(9.1%) 0.20 (0.08–0.53) 0.24 (0.08–0.75)5
(22.9%) 0.81 (0.53–1.25) 0.84 (0.53–1.33)5
3 (16.5%) 0.59 (0.37–0.93) 0.54 (0.33–0.88)4
7 (17.9%) 0.63 (0.45–0.89) 0.63 (0.45–0.90)4
(7.9%) 0.37 (0.18–0.78) 0.37 (0.17–0.78)
8 (2.4%) 0.37 (0.19–0.73) 0.34 (0.15–0.79)
6 (30.8%) 1.14 (0.72–1.79) 0.95 (0.57–1.56)
(40.9%) 1.38 (0.83–2.29) 0.91 (0.47–1.77)
(41.0%) 1.31 (0.97–1.78) 1.24 (0.88–1.74)4
3 (53.4%) 1.71 (1.34–2.18) 1.58 (1.21–2.06)4
07 (50.2%) 1.61 (1.30–1.99) 1.50 (1.22–1.86)
(29.2%) 1.03 (0.72–1.49) 1.03 (0.71–1.49)
8 (12.9%) 1.27 (0.90–1.79) 0.99 (0.57–1.73)
cluding partially vaccinated children and children with unknown vaccination status,
en 1–4 years is compared to carriage in 2009–2011 (pre-PCV13 period; all unvac-
who were eligible for PCV13 in the catch-up cohort but received no vaccination, and
ehold, age, and within-person clustering (mother only). Using a generalized linear
5–15 years of age (r2 < 0.01), hence results from a (non-mixed) generalized linear
nce for mothers was 0.68 (all serotypes)/1.25 (PCV13)/1.03 (non-PCV13).
el with robust standard errors are presented.
Fig. 4. Kaplan-Meier plot for time to first pneumococcal carriage acquisition of any serotype (A) or a vaccine serotype (B) in infants in Karonga District, Malawi, pre and post
introduction of PCV13. Observations in the pre-PCV13 period right-truncated at 18 weeks (maximum observation period post-PCV13 period).
E. Heinsbroek et al. / Vaccine 36 (2018) 7369–7376 7375Although a reduction of VT carriage was observed in vaccinated
children 1–4 years, carriage prevalence remained a relatively high
17%. Similar results were found in studies in Kenya [25], The Gam-
bia [27] and South Africa [28], also conducted two years post PCV
introduction; although VT carriage was reduced post vaccine
introduction in all three sites, VT carriage was sustained at 13%
in children <5 years in Kenya, at 24% in <2 year-olds and 29% in
2–5 year-olds in South Africa, and at 18% in 6–11 month-olds in
the Gambia (Supplementary Table 1). These estimates are much
higher than the <1–4% VT carriage in vaccinated children observed
after PCV introduction in high-income countries [29–31]. Results
from a more recent study conducted in Kenya show that VT car-
riage in children <5 years further reduced to 9% in the five years
post PCV introduction, suggesting an ongoing but delayed effect
[26]. Results from a recent cross-sectional survey in Blantyre, an
urban city in southern Malawi, also show that VT carriage can be
sustained years after PCV13 introduction: VT carriage prevalence
of 20% was observed in vaccinated 3–6 year-olds in 2017, more
than five years post introduction of the vaccine [32].
We have evidence of an indirect effect in older children and
adults, but indirect effects may be absent or perhaps more plausi-
bly delayed in unvaccinated younger age groups. VT carriage was
reduced in unvaccinated children 1–4 years, but this reduction
did not reach statistical significance, and no reduction was
observed in the pre-vaccine 6-week age group. Differences in herd
benefit are likely a result of different contact patterns between age
groups [33], in combination with differences in naturally acquired
immunity. Exposure analyses from the pre-PCV13 period suggest
that infant-to-mother and infant-to-sibling transmission fre-
quently occurs [5] and it is likely that this will have been an impor-
tant contributing factor to the herd effect in older children and
mothers observed. Children <5 years do not yet have optimal nat-
ural acquired immunity, yet do experience a high force of infection
[32] which could explain the delay of herd benefit observed in this
young age group. Results from the carriage study in Blantyre,
southern Malawi suggest that development of indirect protection
in unvaccinated children is delayed, but does develop over time:
VT carriage among unvaccinated children 5–10 years was 28% in
2015, but dropped to 10% in 2017 [32]. Our study was conducted
only 2.5 years after PCV13 introduction; it is probable that a fur-
ther drop in VT carriage in all age groups has occurred now that
the vaccinated population has increased in size.
Sustained VT carriage in vaccinated children is likely to be a
result of re-colonisation after waning mucosal immunity [32],
and suggests that a booster dose is essential to prolonganti-carriage immunity. A ‘2 + 10 schedule with the booster dose
of PCV13 given at 9 months to coincide with measles vaccination
should be assessed for its effect on delaying the waning of mucosal
immunity in vaccinated individuals, and for its subsequent effect
on herd immunity, particularly in the unvaccinated younger age
groups. In addition, a further booster dose may be required in
the second year of life or at pre-school age to sustain anti-
carriage immunity. Although this would increase vaccine costs this
may be essential to generate herd protection and may only be
required until herd protection is achieved.
Countries newly introducing PCV should further consider
implementing a catch-up campaign with a broader age range
than was implemented in Malawi. In Malawi, a 3-dose catch-up
campaign was conducted for infants up to one year of age, for
which moderate coverage was achieved (49.8% for 3 doses
PCV13) in Karonga District [18]. In Kilifi County in Kenya, where
PCV10 was introduced in 2011 with a catch-up campaign for chil-
dren <5 years, VT carriage declined in all age groups within
6 months of PCV10 introduction [25], suggesting that a broader
catch-up campaign is essential to obtain a more immediate herd
impact.
Any before/after study suffers from potential bias from underly-
ing temporal change in carriage prevalence independent of the
vaccine effect, which may be difficult to assess. There were no
other known interventions, secular changes or social patterning
over this period that would have impacted on pneumococcal car-
riage. Although a cookstove trial was conducted in this population
in 2014 [34], there was no evidence that the intervention clusters
had different rates of carriage (unpublished results). We are confi-
dent that a vaccine effect largely explains our measured differ-
ences. VT carriage was reduced most in the vaccinated groups
and there was some evidence of dose response with greater reduc-
tions observed with more doses of vaccine. We used slightly differ-
ent recruitment methods in 2014 based on experience in 2009–11,
but compared seasonally-matched periods.
Our laboratory procedures did not allow for detection of simul-
taneous colonization with multiple serotypes and previous work
suggests this is common in this population [35,36]. This will not
have influenced our comparisons between the pre- and post-
PCV13 period, but will have decreased the accuracy of our esti-
mates of carriage prevalence. Our study was not powered to assess
changes in individual serotypes and our laboratory procedures did
not differentiate individual NVT; we can therefore not assess
whether individual serotypes have increased or decreased since
PCV13 introduction.
7376 E. Heinsbroek et al. / Vaccine 36 (2018) 7369–7376In conclusion, three years post PCV13 introduction in Malawi,
we observed changes in pneumococcal epidemiology consistent
with direct and herd effects. Despite the observed direct and herd
effects, VT carriage was sustained at 17% in vaccinated children
1–4 years, and no clear reduction was observed in the unvacci-
nated under 5 s and the pre-vaccine 6-week age group. Our results
suggest that although the current 3 + 0 schedule has had an impact
on VT carriage in Malawi, different schedules including a booster
dose may need to be assessed in order to obtain and maintain pro-
tection of the younger age groups until a more population-wide
herd protection is achieved.
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